Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 New trial record